期刊文献+

血小板活化因子在急性冠脉综合征患者中的变化 被引量:8

The change of plasma platelet activating factor (PAF) and thromboxane B_2 (TXB_2) in patients with acute coronary syndrome (ACS)
原文传递
导出
摘要 目的测定急性冠脉综合征(acute coronary syndromes,ACS)患者血浆血小板活化因子 (platelet activating factor,PAF)和血栓烷B2(thromboxane B2,TXB2)水平,研究其含量变化在ACS发生、发展中的意义。方法分别采用反相高效液相色谱法(rHPLC)、放射免疫法(RIA)测定40例ACS患者(其中急性心肌梗死AMI 15例,不稳定型心绞痛UAP 25例)刚入院、入院24 h、入院72 h和40例健康对照组血浆PAF、TXB2值。结果 AMI组患者血浆PAF、TXB2均显著高于对照组,差异具有显著性(P<0.01), 并至少持续到72 h。PAF在入院后24 h最高,三个时间组相比差异有显著性(P<0.01)。TXB2三个时间组相比差异没有显著性(P>0.05)。UAP组刚入院、入院24 h、入院72 h的PAF和TXB2略高于对照组,但差异没有显著性(P>0.05)。AMI组PAF、TXB2值显著高于UAP组,差异有显著性(P<0.01)。结论 PAF、TXB2在ACS的发生、发展中发挥了重要作用。血浆PAF、TXB2水平的检测,对ACS诊断、疗效和预后判断具有指导意义。 Objective To determine the plasma levels of PAF and TXB2 of patients with ACS, and to study significance in the progress of ACS. Methods Patients were divided into two groups: acute myocardial infarction (AMI) group ( n = 15) and unstable angina pectoris (UAP) group ( n = 25). PAF and TXB2 were measured on admission, at 24 hours and at 72 hours after admission in 40 patients with ACS and 40 control volunteers. Plasma PAF and TXB2 levels were measured by reversed phase high-performance liquid chromatographic technique (rHPLC) and radi y (RIA) Results PAF and TXB2 levels were higher in patients with AMI than those in normal volunteers (P 〈 0.01 ), the increased levels lasted at least 72 hours. Compared to admission, PAF at 24 hours and 72 hours were signifieantly increased (P 〈 0.01 ). There was no significant difference in TXB2 (P 〉 0.05). PAF and TXB2 levels were higher in patients with UAP than those in normal volunteers ( P 〉 0.05 ). PAF and TXB2 in AMI were higher than those in UAP ( P 〈 0.01 ). Conclusion PAF and TXB2 played important roles in occurrence and development of ACS. The measurement of PAF and TXB2 was useful in diagnosis, treatment, and predicting prognosis of ACS.
出处 《中华急诊医学杂志》 CAS CSCD 2006年第5期451-453,共3页 Chinese Journal of Emergency Medicine
基金 浙江省医药卫生科学研究基金资助项目(2000A100 2004B068)
关键词 急性冠脉综合征 血小板活化因子 血栓烷B2 Acute coronary syndromes Platelet activating factor Thromboxane BE
  • 相关文献

参考文献15

  • 1Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome [J]. Am Fain Physician, 2005, 72 (1): 119-126.
  • 2Heuseh G, Schulz R, Haude M, et al. Coronary mieroembolizafion[J]. J Mol Cell Cardiol, 2004, 37 (1): 23-31.
  • 3Gotlieb AI. Atherosclerosis and acute coronary syndromes [ J ].Cardiovasc Pathol, 2005, 14 (4): 181-184.
  • 4Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability[J]. Mt Sinai J Med, 2006, 73 (1): 431-439.
  • 5Stefan B, Dominique S, Hans JR, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis [J]. Lipid Res, 2003, 44 (7): 1381-1386.
  • 6曹红翠,许文荣,朱伟,陈晓明,李兰娟.血小板活化因子反相高效液相色谱法测定及其在老年性疾病中的应用[J].临床检验杂志,2003,21(3):129-131. 被引量:8
  • 7Shin J, Edelberg JE, Hong MK. Vulnerable atherosclerotic plaque:clinical implications [J]. Curr Vasc Pharmacol, 2003, 1 (2): 183-204.
  • 8Liuzzo G, Giubilato G, Pinnelli M. T cells and cytokines in atherogenesis [J]. Lupus, 2005, 14 (9): 732-735.
  • 9Klein LW. Clinical implications and mechanisms of plaque rupture in the acute coronary syndromes [J]. Am Heart Hosp J, 2005, 3 (4) :249-255.
  • 10Zimmerman GA, McIntyre TM,Prescott SM.et al.The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis[J].Crit Care Med.2002.30(5Suppl):294-301.

二级参考文献20

  • 1Zimmerman G A McIntyre T M Prescott S M et a1.The p1ate1et-activating factor signa1ing system and its regu1ators in syndromes of inf1ammation and thrombosis[J].Crit Care Med,2002,30(5):294-301.
  • 2孙毓庆 王延琮.现代色谱法及其在医药中的应用[M].北京:人民卫生出版社,2000.180-222.
  • 3曹红翠 林江.血小板异常性疾病及其实验诊断[A].见许文荣.临床血液学检验[C].南京:东南大学出版社,2001.149-159.
  • 4Chung K F. Platelet activating factor revisited[ J]. Thorax, 1997,52(12) :1019-20.
  • 5Rao G H. Role of platelet adhesion and aggregation in thrombus formation [J] .Thromb Haemost, 1998,79:454-455.
  • 6Silvestro L, Col R D, Scappaticci L, et al. Development of a highperformance liquid chromatographic-mass spectrometricc technique with an ionspray interface for the determination of platelet-activating factor(PAF)and lyso-PAF biological samples [ J ]. Journal of Chromatography , 1993,647: 261-269.
  • 7Ammit A J, Oneill C. Studies of the nature of the binding by albumin of platelet-activating factor released from cells[J] .J Bid Chem, 1997,272(30) : 18772-18778.
  • 8Servillo L,Iorio E L, Quagliuolo L et al. Simultaneous determination of lysophosphulipies by high-performance liquid chromatography with flunrescence detection[J].J Chromatogr B Biomed Sci Appl,1997,21:689(2):281-286.
  • 9Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent Claudication. Incidence in the Framingham Study. Circulation, 1970,41 (10): 875-883.
  • 10Shinichi S, Masakazu N, Minoru L, et al. Plasma fibrinogen and coronary heart disease in Urban Japanese. J Am Epid, 2000, 152(5), 420-431.

共引文献14

同被引文献60

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部